Stock AnalizHalozyme Therapeutics, Inc. HALO
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Halozyme Therapeutics, Inc. (HALO) is a healthcare company listed in the US with a market value of about $11.4B. In the twelve months to September 30, 2026 it had revenue of $1.8B and net income of $485M, a net margin of 26.9%.
Its overall Stock Analiz score is 3.4 out of 5 (good). The strongest part is track record (5/5); the weakest is financial health (2/5).
Key numbers: a P/E of 25.0, a price to free cash flow of 12.9, 5-year revenue growth of 39% a year, a 5-year average ROIC of 17%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 199% above the current price.
Score: 3.4 / 5
Checks passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Checks not passed
- P/E below 25
- P/E below the industry median
- Profit margin improving
- More cash than debt, or low debt to equity
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
- Pays a dividend
- Dividend 3 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8B | $1.4B | $1.0B | $829M | $660M | $443M | $268M | $196M | $152M | $317M | $147M |
| Net income | $485M | $317M | $444M | $282M | $202M | $403M | $129M | -$72M | -$80M | $63M | -$103M |
| Free cash flow | $886M | $645M | $468M | $373M | $235M | $298M | $53M | -$89M | -$54M | $133M | -$54M |
| EPS (diluted) | $4.01 | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 | $0.91 | $-0.50 | $-0.56 | $0.45 | $-0.81 |
| Net margin | 26.9% | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | 48.2% | -36.9% | -52.9% | 19.9% | -70.2% |
| ROIC | — | 14.3% | 23.1% | 16.9% | 12.7% | 20.2% | 26.0% | -13.5% | -14.6% | 15.6% | -35.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $119.89, 20% above the current price; targets range from $79.00 to $149.00; the consensus rating is “Buy”; expected EPS is $8.89 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Halozyme Therapeutics’s P/E ratio?
About 25.0, based on the last twelve months of diluted earnings per share (forward P/E about 9.8).
Is Halozyme Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 199% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Halozyme Therapeutics pay a dividend?
Not currently.
Is Halozyme Therapeutics a good stock to buy?
We do not give buy or sell advice. Halozyme Therapeutics scores 3.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.